|
|
|
|
|
|
|
|
Two trials provided new data on Yondelis(R) (trabectedin), a marine-based anti-tumor drug currently produced by chemical synthesis. Yondelis(R) (trabectedin) has European Commission approval for advanced and metastatic soft tissue sarcoma (STS) and for recurrent platinum-sensitive ovarian cancer in combination with Doxil/Caelyx
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.